Remedent (Remedent) Change In Working Capital : $0.26 Mil (TTM As of Dec. 2020)

View and export this data going back to 2000. Start your Free Trial

What is Remedent Change In Working Capital?

Remedent's change in working capital for the quarter that ended in Dec. 2020 was $0.01 Mil.

Remedent's change in working capital for the fiscal year that ended in Mar. 2020 was $0.56 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Remedent Change In Working Capital Historical Data

The historical data trend for Remedent's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Remedent Change In Working Capital Chart

Remedent Annual Data

Trend

Mar11

Mar12

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Change In Working Capital

Get a 7-Day Free Trial

-0.31

1.97

0.13

1.30

0.56

Remedent Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Change In Working Capital	Get a 7-Day Free Trial															0.15	0.28	-0.01	-0.02	0.01

Remedent Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.26 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Remedent Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Remedent's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Remedent (Remedent) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Remedent Inc (OTCPK:REMI) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Zuiderlaan 1-3, Box 8, Ghent, BEL, 9000

Website

https://www.remedent.com

Remedent Inc is a manufacturer of cosmetic dentistry products in Europe. The company is engaged in the research, development, and manufacturing of oral care and cosmetic dentistry products. It designs, develops, manufactures, and distributes cosmetic dentistry products, including a full line of professional dental products that are distributed in Europe, Asia, the Middle East, and the United States. The product line of the company includes SmileWise, the SmileMe mirror, and the Condor intra-oral 3D scanner.

Executives

Stuart Steinberg	10 percent owner	85 BELLEVUE AVENUE, RYE NY 10580
Marxe Austin W & Greenhouse David M	10 percent owner	C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Gruber & Mcbaine Capital Management Llc	10 percent owner	234 VAN NESS, STE 5, SAN FRANCISCO CA 94133
Stephen Farley Ross	director, officer: CFO; Secretary	XAVIER DE COCKLAAN 42 DEURLE C9 9831
Fred Kolsteeg	director	XAVIER DE COCKLAAN 42 DEURLE C9 9831
Acker Philippe Van	director	C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 9831 DEURLE C9 9831
Robin List	other: Former Officer and Director	XAVIER DE COCKLAAN 42 DEURLE C9 9831
Roger Leddington	officer: Sr VP & Head of US Marketing	C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 DEURLE C9 9831
Guy Devreese	director, officer: Chairman of the Board	XAVIER DE COCKLAAN 42 DEURLE C9 9831
Judd Darrin Hoffman	officer: VP Worldwide Sales/Operations	702A JUANITA AVENUE REDONDO BEACH CA 90277
Nv Lausha	10 percent owner	C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 9831 DEURLE C9 9831

Remedent (Remedent) Headlines

From GuruFocus

Making Money from Smiles

By Frank Lind Frank Lind • 05-26-2011